Carcinoma in situ of skin of other and unspecified parts of face
ICD-10 D04.3 is a billable code used to indicate a diagnosis of carcinoma in situ of skin of other and unspecified parts of face.
Carcinoma in situ (CIS) of the skin represents a localized, non-invasive form of skin cancer where abnormal cells are present but have not invaded deeper tissues. Specifically, D04.3 refers to CIS located in other and unspecified parts of the face, which may include areas such as the forehead, cheeks, or around the eyes and mouth. This condition is characterized by the presence of atypical keratinocytes confined to the epidermis, and it is often detected through skin examinations or biopsies. Risk factors for developing CIS include prolonged sun exposure, fair skin, and a history of skin cancer. Surveillance protocols typically involve regular dermatological evaluations to monitor for changes in the lesion, as well as patient education on sun protection and skin self-examinations. The risk of progression to invasive carcinoma is present, particularly if left untreated, making early detection and intervention critical.
Detailed descriptions of the lesion, including size, location, and characteristics.
Diagnosis of CIS during routine skin checks, biopsy results indicating CIS.
Ensure that all findings are clearly documented to support the diagnosis and coding.
Comprehensive treatment plans and follow-up notes.
Management of CIS with topical therapies or surgical excision.
Documenting the rationale for treatment choices and monitoring for progression.
Used when a biopsy is performed to confirm carcinoma in situ.
Pathology report confirming carcinoma in situ must be included.
Dermatologists should ensure that the biopsy site is clearly documented.
Carcinoma in situ is a critical diagnosis as it indicates the presence of abnormal cells that have not invaded surrounding tissues. Early detection and treatment are essential to prevent progression to invasive cancer.
